Pentapharma SRL
Pentapharma reported total assets of 76,887 € at the end of the 2025 financial year (annual accounts filed with the NBB on 13 Jul 2026).
The score of Pentapharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +25 % Total assets -7 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pentapharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 13 Jul 2026
- Year ended 31 Dec 2024filed on 12 Jul 2025
- Year ended 31 Dec 2023filed on 08 Jul 2024
- Year ended 31 Dec 2022filed on 27 Jun 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
Pentapharma's financial analysis
- Solvency50.0%sector median: 60.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pentapharma
Pentapharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0666.417.120
- VAT number
- BE0666417120
- Peppol
- Registered · 0208:0666417120 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 Nov 2016
- Registered office
- 8630 Veurne
- Latest accounts
- 2025 · filed on 13 Jul 2026
- Activity
- Market research and public opinion polling (NACE 73200)
Pentapharma (SRL) has been based in Veurne since 2016, active in: market research and public opinion polling. For 2025, it reports a net profit of 2,769 € and equity of 38,418 €; its revenue is not published. Its solvency stands at 50.0%, below the median of its sector (60.5%).
Companies similar to Pentapharma
Companies in the same business, of comparable size and area, outside its group.
- The Product Architects Market research and public opinion polling Antwerp · balance sheet 75,271 €
- Ergo Soft Market research and public opinion polling Liège · balance sheet 74,048 €
- Cross ET Cable Market research and public opinion polling Brussels · balance sheet 80,036 €
- D-Touch Market research and public opinion polling Ghent · balance sheet 93,397 €
- Forton Consulting Market research and public opinion polling Villers-la-Ville · balance sheet 73,468 €
- Entregent Market research and public opinion polling Ixelles · balance sheet 80,651 €
- Synergies ET Actions Market research and public opinion polling Schaerbeek · balance sheet 73,257 €
- Prebia Market research and public opinion polling Destelbergen · balance sheet 72,960 €
Frequently asked questions about Pentapharma
What is the revenue of Pentapharma?
Pentapharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pentapharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0666417120 for Pentapharma, if the company is VAT-registered. Its company number (CBE) is 0666.417.120.
Where is the registered office of Pentapharma?
According to the CBE register, the registered office of Pentapharma is in 8630 Veurne.
What is the equity of Pentapharma?
At the close of the 2025 financial year, the equity of Pentapharma amounts to 38,418 €, a solvency of 50.0% of total assets.
Who manages Pentapharma?
The register lists 3 active mandates at Pentapharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pentapharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →